Phosphatase PTP4A3 flags poor-outcome AML and yields to inhibition, boosting cytarabine in cell models
- Public leukemia datasets link high PTP4A3 expression to poorer patient outcomes, unstable genomes and heightened oncogenic signaling in acute myeloid leukemia.
- Blocking the phosphatase with the inhibitor JMS-053 in leukemia cell lines curbed viability and colony formation, triggered apoptosis, and gradually dampened ERK1/2 phosphorylation.
- Combining JMS-053 with cytarabine produced synergistic effects, supporting PTP4A3 as both a risk marker and a candidate target; findings are preclinical.
💡 Points Based on the abstract
Phosphatases have a poor druggability record, and JMS-053 is a tool compound, not a drug. It is a thienopyridone-type inhibitor with a history of redox and selectivity worries across the PTP family. Before I'd believe the ERK1/2 story or the cytarabine synergy, I'd want a PTP4A3 knockdown or catalytic-dead rescue to rule out off-target effects. Next: patient-derived blasts, plus an in vivo xenograft with measured exposure.